{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-193945","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.897540+00:00","generated_at":"2026-05-15T01:02:36.857745+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phathom Pharma Q1 net rev $58.3M (+104% YoY); maintains FY 2026 op profitability guidance","bullets":["Q1 net revenues $58.3M vs $28.5M YoY; net loss $30.4M vs $94.3M YoY.","Non-GAAP operating expenses $56.2M, down ~43% YoY; cash and equivalents $180.9M.","~1.35M total VOQUEZNA prescriptions filled to date; Q1 covered prescriptions up 91% YoY.","FY 2026 guidance: net rev $320-345M, non-GAAP op ex $235-255M; op profitability expected Q3 2026.","EoE phase 2 trial (pHalcon-EoE-201) topline results expected late Q4 2026/early Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-193945","json":"https://secwatch.observer/filing/0001193125-26-193945.json","markdown":"https://secwatch.observer/filing/0001193125-26-193945.md","text":"https://secwatch.observer/filing/0001193125-26-193945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526193945/0001193125-26-193945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526193945/d140332d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:02:36.857745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5041010f01ae977cd374a48ce01a91e7a75d704a","claim":"Phathom Pharmaceuticals, Inc. reported the first quarter ended March 31, 2026 results: revenue $58.3 million. Guidance reaffirmed.","evidence_excerpt":"Exhibit 99.1 Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update • ~1.35 million total VOQUEZNA ® prescriptions filled to date • $58.3 million in Q1 net revenues, a 104% increase year-over-year • Q1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2 million and net cash usage of ~$15 million,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526193945/0001193125-26-193945-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$58.3 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}